Evolus, Inc. (EOLS)

NASDAQ: EOLS · IEX Real-Time Price · USD
11.65
-0.40 (-3.32%)
Apr 17, 2024, 3:40 PM EDT - Market open
-3.32%
Market Cap 718.91M
Revenue (ttm) 202.09M
Net Income (ttm) -61.69M
Shares Out 61.50M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 175,029
Open 12.05
Previous Close 12.05
Day's Range 11.62 - 12.12
52-Week Range 7.07 - 15.43
Beta 1.45
Analysts Strong Buy
Price Target 21.83 (+87.38%)
Earnings Date May 7, 2024

About EOLS

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California. [Read more]

Sector Healthcare
IPO Date Feb 8, 2018
Employees 273
Stock Exchange NASDAQ
Ticker Symbol EOLS
Full Company Profile

Financial Performance

In 2023, Evolus's revenue was $202.09 million, an increase of 35.98% compared to the previous year's $148.62 million. Losses were -$61.69 million, -17.10% less than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price forecast is $21.83, which is an increase of 87.38% from the latest price.

Price Target
$21.83
(87.38% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qu...

4 days ago - Business Wire

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...

22 days ago - Business Wire

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of...

5 weeks ago - Business Wire

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its fina...

5 weeks ago - Business Wire

Evolus Announces Results from European Head-to-Head Filler Trial

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will provi...

6 weeks ago - Business Wire

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences.

7 weeks ago - Business Wire

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--To participate in the conference call, dial (877) 407-6184 or (201) 389-0877 or join the webcast on the Investor Relations page of the Evolus website.

7 weeks ago - Business Wire

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations.

3 months ago - Business Wire

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagheri...

3 months ago - Business Wire

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced it has entered into a definitive agre...

4 months ago - Business Wire

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results f...

5 months ago - Business Wire

“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced results from the Phase 2...

5 months ago - Business Wire

Evolus to Participate in November Investor Conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of it...

6 months ago - Business Wire

Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox...

6 months ago - Business Wire

Evolus to Report Third Quarter 2023 Results

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...

6 months ago - Business Wire

Evolus to Participate in September Conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of it...

8 months ago - Business Wire

Evolus Announces Inducement Grants for New Chief Marketing Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Compensat...

8 months ago - Business Wire

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today.

8 months ago - Business Wire

Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus unveils fresh, new branding for its flagship neurotoxin product, Jeuveau.

9 months ago - Business Wire

Evolus Reports Second Quarter 2023 Results and Provides Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus reported financial results for the second quarter ended June 30, 2023 and provided a business update.

9 months ago - Business Wire

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus reported revenue for the second quarter ended June 30, 2023 and raised its revenue guidance for the full year.

9 months ago - Business Wire

Evolus to Participate in Canaccord Genuity's 43rd Annual Growth Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus announced that members of its management team will be participating in Canaccord Genuity's 43rd Annual Growth Conference in Boston.

9 months ago - Business Wire

Evolus to Report Second Quarter 2023 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus announced that it will report its second quarter 2023 financial results and provide a business update on Wednesday, August 2, 2023.

9 months ago - Business Wire

Evolus Launches Nuceiva® (botulinum toxin type A) in Italy

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. has commenced the commercial launch of Nuceiva® in Italy. The product is now available for direct order and delivery to customers.

10 months ago - Business Wire

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. announced the completion of its Phase 2 clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau®.

10 months ago - Business Wire